FDA Designates Axatilimab an Orphan Drug for IPF

FDA Designates Axatilimab an Orphan Drug for IPF

291617

FDA Designates Axatilimab an Orphan Drug for IPF

Axatilimab, an investigational therapy being developed by Syndax Pharmaceuticals, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) as a potential treatment for idiopathic pulmonary fibrosis (IPF). The FDA gives orphan drug status to medications that have the potential to substantially improve care for people with rare diseases — defined as those affecting fewer than 200,000 people in the U.S. The designation qualifies therapy developers for certain incentives, including tax…

You must be logged in to read/download the full post.